Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China
US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical...
HKG: 1093
CSPC Pharmaceutical Group Gets NMPA Approval for JMT203 Cancer Cachexia Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...
CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
CSPC Pharmaceutical’s CPO301 Receives Health Canada Approval for Phase I Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Chinese Pharma Companies Update Pipelines at ASCO 2023 Annual Meeting
A number of Chinese pharmaceutical companies have shared updates on their pipeline developments at the...
CSPC Pharmaceutical Group Partners with China Unicom for Digital Transformation
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a strategic partnership with Chinese mobile...
CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...
Alphamab Oncology and CSPC Pharma Get Green Light for KN026 Phase III Study in Breast Cancer
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced receiving...
CSPC Pharmaceutical Group Reports 11% YOY Revenue Growth in 2022 Financial Results
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has released its 2022 financial report, recording RMB...
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market...
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial...
CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has obtained an Emergency...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency...
CSPC Pharmaceutical’s PD-1 Monoclonal Antibody Enlangsubai Completes NMPA Market Approval Filing
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the completion of a market approval...
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...
CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...